CA3011683C - Methods and compositions for treating hyperhidrosis - Google Patents

Methods and compositions for treating hyperhidrosis Download PDF

Info

Publication number
CA3011683C
CA3011683C CA3011683A CA3011683A CA3011683C CA 3011683 C CA3011683 C CA 3011683C CA 3011683 A CA3011683 A CA 3011683A CA 3011683 A CA3011683 A CA 3011683A CA 3011683 C CA3011683 C CA 3011683C
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
hyperhidrosis
use according
pilocarpine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3011683A
Other languages
English (en)
French (fr)
Other versions
CA3011683A1 (en
Inventor
Benjamin F. Mcgraw, Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravida Inc
Original Assignee
Theravida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravida Inc filed Critical Theravida Inc
Publication of CA3011683A1 publication Critical patent/CA3011683A1/en
Application granted granted Critical
Publication of CA3011683C publication Critical patent/CA3011683C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
CA3011683A 2016-01-20 2016-01-20 Methods and compositions for treating hyperhidrosis Active CA3011683C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/014150 WO2017127073A1 (en) 2016-01-20 2016-01-20 Methods and compositions for treating hyperhidrosis

Publications (2)

Publication Number Publication Date
CA3011683A1 CA3011683A1 (en) 2017-07-27
CA3011683C true CA3011683C (en) 2023-09-26

Family

ID=59314209

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3011683A Active CA3011683C (en) 2016-01-20 2016-01-20 Methods and compositions for treating hyperhidrosis

Country Status (15)

Country Link
US (4) US10328057B2 (enExample)
EP (1) EP3405191B1 (enExample)
JP (1) JP6841834B2 (enExample)
KR (2) KR102600541B1 (enExample)
CN (1) CN108697688A (enExample)
AU (2) AU2016388308B2 (enExample)
BR (1) BR112018014661A2 (enExample)
CA (1) CA3011683C (enExample)
DK (1) DK3405191T3 (enExample)
HK (1) HK1258825A1 (enExample)
MX (1) MX394356B (enExample)
RU (1) RU2718906C2 (enExample)
TW (2) TW202341976A (enExample)
WO (1) WO2017127073A1 (enExample)
ZA (1) ZA201805490B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3061821B1 (en) 2009-07-22 2019-07-10 Puretech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
WO2017127073A1 (en) 2016-01-20 2017-07-27 Theravida, Inc. Methods and compositions for treating hyperhidrosis
IL281809B (en) 2018-09-28 2022-09-01 Karuna Therapeutics Inc Compositions and methods for the treatment of diseases improved by the activation of muscarinic receptors
PH12021553026A1 (en) 2019-07-05 2023-08-23 Swedish Match North Europe Ab An oral pouched nicotine product including a filling material comprising nicotine-containing particles
KR102849937B1 (ko) 2019-11-20 2025-08-25 스웨디쉬 매치 노스 유럽 에이비 니코틴 입자를 포함하는 충전 재료를 포함하는 경구 파우치형 니코틴 제품
EP3967311A1 (en) * 2020-09-11 2022-03-16 Astellas Pharma Inc. Compounds for use in the treatment of dry mouth
EP4018849B1 (en) 2020-12-22 2024-10-23 Swedish Match North Europe AB A pouched product for oral use
PL4018847T3 (pl) 2020-12-22 2024-11-18 Swedish Match North Europe Ab Produkt w saszetce do stosowania doustnego
EP4018848B1 (en) 2020-12-22 2024-09-18 Swedish Match North Europe AB A pouched product for oral use comprising a liquid permeable cover material and a filling material
EP4384158A4 (en) * 2021-08-11 2025-07-02 Theravida Inc PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERHIDROSIS
TR2023000985A2 (tr) * 2023-01-27 2023-02-21 Ardi Farma Ilac Pazarlama Ticaret Ltd Sirketi Kontrollü salim sağlayan propi̇veri̇n formülasyonu

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209505A (en) 1979-04-03 1980-06-24 Mikhail Adib R Pilocarpine mouthwash for dry mouth relief
US4302440B1 (en) * 1980-07-31 1986-08-05 Easily-swallowed, powder-free and gastric-disintegrable aspirin tablet thinly-coated with hydroxypropyl methylcellulose and aqueous spray-coating preparation thereof
SE450087B (sv) 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
DK0746310T3 (da) 1994-02-23 1999-08-02 Bm Res As Præparat med styret afgivelse
US5674895A (en) 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
CA2277220A1 (en) 1997-01-10 1998-07-16 Abbott Laboratories Tablet for the controlled release of active agents
WO1998042318A1 (en) * 1997-03-26 1998-10-01 Janssen Pharmaceutica N.V. Pellets having a core coated with an antifungal and a polymer
DK1685839T3 (da) 1997-12-22 2013-06-24 Euro Celtique Sa Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
CN1204890C (zh) 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
US6482837B1 (en) 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
US5997905A (en) 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
WO2000024423A1 (en) 1998-10-26 2000-05-04 Tanabe Seiyaku Co., Ltd. Sustained-release particles
FR2795962B1 (fr) 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
CN101288663A (zh) 1999-09-14 2008-10-22 史密丝克莱恩比彻姆公司 制备水性包被小球粒的方法
DE60021749T2 (de) 1999-11-11 2006-04-20 Pfizer Health Ab Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung
US20030018061A1 (en) 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
JP2005521706A (ja) 2002-03-29 2005-07-21 アルザ・コーポレーシヨン 体積効果的放出制御製剤
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
WO2004105735A1 (en) 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
AU2004263130A1 (en) 2003-08-06 2005-02-17 Nirmal Mulye Pharmaceutical composition containing water soluble drug
DK2210605T3 (en) 2003-11-04 2017-05-22 Tcd Royalty Sub Llc Daily single dose doses of trospium.
ZA200701576B (en) 2004-04-30 2008-09-25 Astellas Pharma Inc Time-limited release type granular pharmaceutical composition for oral administration and intraoral rapid disintegration tablet containing the composition
WO2005115340A1 (en) 2004-05-19 2005-12-08 Glatt Air Techniques, Inc. Micropellet containing pellets and method of preparing such pellets
EP1753405A4 (en) 2004-06-10 2008-09-17 Glatt Air Tech Inc SLOW RELEASE PHARMACEUTICAL PREPARATION
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
JP2008516893A (ja) 2004-08-27 2008-05-22 スフェリックス，インク． 多層錠剤および生体接着性剤形
WO2006132196A1 (ja) 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation β３作動薬を含有する新規な医薬
PL1933833T3 (pl) * 2005-09-02 2011-09-30 Theravida Inc Terapia do leczenia pęcherza nadreaktywnego
WO2007029087A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Controlled release multiple unit formulations
US20070077300A1 (en) 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
CN101340884A (zh) * 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 用于治疗多汗症的方法
CA2680680A1 (en) 2007-03-29 2009-02-19 Panacea Biotec Limited Modified dosage forms of tacrolimus
US7563508B2 (en) 2007-05-30 2009-07-21 Chung Shan Institute Of Science And Technology, Armaments Bureau, M.N.D. Diffusion beads with core-shell structure
US20090017111A1 (en) 2007-07-03 2009-01-15 Van Den Heuvel Dennie J M Tolterodine bead
US8110226B2 (en) 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US9561015B2 (en) * 2007-08-24 2017-02-07 General Electric Company Method and apparatus for voice recording with ultrasound imaging
WO2009045796A1 (en) 2007-09-28 2009-04-09 Novartis Ag Pharmaceutical combination of aliskiren and valsartan
JP2011502140A (ja) 2007-10-29 2011-01-20 ルピン・リミテッド トルテロジンの制御放出型医薬組成物
US20090192228A1 (en) 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090247628A1 (en) * 2008-03-25 2009-10-01 Auspex Pharmaceuticals, Inc. Substituted phenylcyclohexylglycolates
KR20130065650A (ko) 2010-04-01 2013-06-19 테라비다, 인코포레이티드 수면의 질 개선 방법
SG174658A1 (en) * 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
WO2012154774A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
US20120289560A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
US20140037713A1 (en) * 2012-08-03 2014-02-06 Antares Pharma Ipl, Ag Transdermal compositions for anti-cholinergic agents
US20140105976A1 (en) 2012-10-11 2014-04-17 Theravida, Inc. Pharmaceutical formulations of pilocarpine
WO2017127073A1 (en) 2016-01-20 2017-07-27 Theravida, Inc. Methods and compositions for treating hyperhidrosis

Also Published As

Publication number Publication date
KR20230021184A (ko) 2023-02-13
KR102600541B1 (ko) 2023-11-08
RU2018128047A (ru) 2020-02-20
US20200188360A1 (en) 2020-06-18
TW202341976A (zh) 2023-11-01
TWI810150B (zh) 2023-08-01
MX394356B (es) 2025-03-24
US20190307727A1 (en) 2019-10-10
HK1258825A1 (zh) 2019-11-22
JP6841834B2 (ja) 2021-03-10
KR102495757B1 (ko) 2023-02-06
RU2718906C2 (ru) 2020-04-15
US11779569B2 (en) 2023-10-10
US20170202778A1 (en) 2017-07-20
AU2016388308A1 (en) 2018-08-02
AU2016388308B2 (en) 2022-08-04
CN108697688A (zh) 2018-10-23
BR112018014661A2 (pt) 2018-12-11
US10610519B2 (en) 2020-04-07
US10328057B2 (en) 2019-06-25
WO2017127073A1 (en) 2017-07-27
US20220047558A1 (en) 2022-02-17
ZA201805490B (en) 2019-11-27
MX2018008694A (es) 2019-05-15
US11185533B2 (en) 2021-11-30
DK3405191T3 (da) 2025-05-19
AU2022206709A1 (en) 2022-08-11
CA3011683A1 (en) 2017-07-27
EP3405191A4 (en) 2019-09-04
TW201737906A (zh) 2017-11-01
EP3405191B1 (en) 2025-02-19
KR20180102649A (ko) 2018-09-17
JP2019506401A (ja) 2019-03-07
EP3405191A1 (en) 2018-11-28
RU2018128047A3 (enExample) 2020-02-20

Similar Documents

Publication Publication Date Title
US11779569B2 (en) Methods and compositions for treating hyperhidrosis
JP2020528075A (ja) 過度の眠気を処置するための方法および組成物
US12528772B2 (en) Formulations of T-type calcium channel modulators and methods of use thereof
KR20170068478A (ko) 불면증을 치료하기 위한 조성물 및 방법
WO2021222342A1 (en) Methods of use of t-type calcium channel modulators
KR20210050585A (ko) 소양증을 치료하는 방법
HK1261838A1 (en) Methods and compositions for treating hyperhidrosis
US20240350420A1 (en) Pharmaceutical compositions and methods for treating hyperhidrosis
RU2377234C2 (ru) Лечение или предупреждение синдрома беспокойных ног с использованием пролекарств аналогов гамк
US20190160030A1 (en) Carboxylic acids for early childhood application

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210107

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250109

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250109

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250109

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251223